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Abstract
Background: Estrogen receptor-α (ERα) is essential for mammary gland development and is a
major oncogene in breast cancer. Since ERα is not colocalized with the cell proliferation marker
Ki-67 in the normal mammary glands and the majority of primary breast tumors, it is generally
believed that paracrine regulation is involved in ERα mediated cell proliferation. In the paracrine
model, ERα-positive cells don't proliferate but will release some paracrine growth factors to
stimulate the neighboring cells to proliferate. In a subpopulation of cancer cells in some primary
breast tumors, however, ERα does colocalize with the cell proliferation marker Ki-67, suggesting
an autocrine regulation by ERα in some primary breast tumors.
Methods: Colocalization of ERα with Ki-67 in ERα-positive breast cancer cell lines (MCF-7, T47D,
and ZR75-1) was evaluated by immunofluorescent staining. Cell cycle phase dependent expression
of ERα was determined by co-immunofluorescent staining of ERα and the major cyclins (D, E, A,
B), and by flow cytometry analysis of ERαhigh cells. To further confirm the autocrine action of ERα,
MCF-7 cells were growth arrested by ICI182780 treatment, followed by treatment with EGFR
inhibitor, before estrogen stimulation and analyses for colocalization of Ki-67 and ERα and cell
cycle progression.
Results: Colocalization of ERα with Ki-67 was present in all three ERα-positive breast cancer cell
lines. Unlike that in the normal mammary glands and the majority of primary breast tumors, ERα
is highly expressed throughout the cell cycle in MCF-7 cells. Without E2 stimulation, MCF-7 cells
released from ICI182780 treatment remain at G1 phase. E2 stimulation of ICI182780 treated cells,
however, promotes the expression and colocalization of ERα and Ki-67 as well as the cell cycle
progressing through the S and G2/M phases. Inhibition of EGFR signaling does not inhibit the
autocrine action of ERα.
Conclusion: Our data indicate that ERα can mediate estrogen-induced cell proliferation in an
autocrine mode in ERα-positive breast cancer cell lines. All of the three ERα-positive cell lines used
in our study showed colocalization of ERα and Ki-67, indicating that these cell lines might be
originated from primary tumor cells with autocrine regulation.
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Background
The ovarian-derived steroid hormone estrogen is one of
the main regulators of mammary epithelial cell prolifera-
tion and differentiation. While estrogen is required for
normal mammary gland development, cumulative expo-
sure to estrogen during a woman's lifetime is a high risk
factor for breast malignancy. The action of estrogen is
exerted by binding and activating the estrogen receptors,
ERα and ERβ. Studies on the expression patterns of estro-
gen receptors and gene knock-out mouse models indicate
that ERα is the primary estrogen receptor for mammary
epithelial cell proliferation and differentiation. While ERα
is expressed exclusively in the epithelial cells, ERβ is
expressed in both epithelial and stromal cells but the
expression of ERβ in the epithelial cells is very weak [1-4].
In ERβ knock-out mice, the mammary glands can still
form the bronchoalveolar structure and lactate normally
[5,6]. In ERα knock-out mice, however, the mammary
gland remains at rudimentary duct stage without further
development [7-9]. While the role of ERβ in breast cancer
is less understood, ERα is one of the most known onco-
genes in breast cancer [10-12]. Abnormal expression of
ERα is found in about 70–80% of human breast cancers,
and about 50% of ERα-positive breast cancer patients
respond to anti-estrogen therapy [10,13]. When overex-
pressed in the mammary gland epithelial cells of trans-
genic mice, ERα leads to mammary malignancy [14,15].
Despite the significant role of ERα in mediating estrogen-
induced cell proliferation in normal mammary develop-
ment and breast cancer, the mechanism is still not fully
understood. In the normal mammary gland, ERα expres-
sion is found only in a subpopulation of the mammary
epithelial cells and the percentage of ERα-positive cells is
affected by the physiologic conditions. Unlike most other
cellular receptors, ERα expression is not found in prolifer-
ating mammary epithelial cells [1-3,16-18]. This observa-
tion leads to the prevailing concept that ERα mediates cell
proliferation in a paracrine manner [1,19]. In this para-
crine model, ERα-positive cells don't proliferate; the ERα-
positive cells, however, when stimulated by estrogen, will
produce and release paracrine growth factors, which in
turn stimulate the neighboring cells to proliferate [1,9].
The EGF family member amphiregulin could be one of
those important paracrine growth factors involved in
ERα-mediated mammary gland epithelial cell prolifera-
tion [20]. It is not clear why ERα-positive cells cannot pro-
liferate, or why ERα does not stimulate cell proliferation
in an autocrine mode or in both autocrine and paracrine
modes. A recent study by Cheng et al. challenged the par-
adigm that ERα cannot mediate ERα-positive cell prolifer-
ation [17]. The authors proposed that ERα is degraded
early in the cell cycle, which accounts for the dissociation
of the ERα-staining and cell proliferation marker.
In contrast to the mechanism in normal mammary tis-
sues, ERα might mediate cancer cell proliferation via para-
crine and/or autocrine modes in primary breast cancers.
In ERα-positive primary breast cancers, the percentage of
ERα-staining cells varies from 10% to 50% or higher
[1,3,21,22]. Most of the ERα-staining cells are not stained
with Ki-67 in these ERα-positive primary breast tumors
[1,3,23,24]. In some primary breast tumors, however,
ERα does colocalize with the cell proliferation marker Ki-
67 in a sub-population of tumor cells; the percentage of
ERα and Ki-67 duel-staining cells varies among different
patients, from 0% to ~5% of total cells [1,3]. The co-stain-
ing of ERα and Ki-67 suggests that ERα-positive cells in
these primary breast tumors might be capable of prolifer-
ating, i.e., ERα might be able to mediate cell proliferation
via autocrine fashion in these primary breast tumor cells.
Using breast cancer cell line models, ERα has been shown
to have non-genomic effect in addition to the traditional
genomic action [25]. In its genomic action as a transcrip-
tional factor, ERα activation in MCF-7 cells can induce the
expression of cyclin D and myc to promote cell cycle pro-
gression [26-29]. When stimulated by estrogen, the effect
on cell proliferation in MCF-7 cells is usually not obvious
until 5–7 days after the stimulation [30-32]. It is not clear
why the impact is delayed for such long time and that
raises the question whether the activation of ERα alone is
sufficient to drive cell cycle progression through all the
phases for mitosis. For the non-genomic action of ERα,
cell signaling initiated from the cell surface can activate
multiple pathways such as the ERK and AKT pathways
[33-35]. Using the EGFR inhibitor, Levine and colleagues
demonstrated that EGFR is required for the cell surface
ERα-activated signaling transduction [35]. Marks and col-
leagues demonstrated that inhibition of the MAPK and
PI3K-AKT pathways can prevent estrogen-induced
mitogenesis in MCF-7 cells [36]. Considering all of the
information derived from different perspectives, it is very
likely that MCF-7 cells and some other ERα-positive
breast cancer cell lines might be regulated by ERα via the
autocrine as well as the paracrine modes. In this study, we
demonstrated that ERα is colocalized with Ki-67 in MCF-
7, T47D, and ZR75-1 cells, the ERα-positive breast cancer
cell lines used in our study. Using MCF-7 cell line, we
demonstrated that ERα is present in all the phases of cell
cycle and activation of ERα in G1 phase promotes cell
cycle progression through mitogenesis, supporting the
autocrine mode of regulation. Finally, we demonstrated
that EGFR activation is not required for the autocrine reg-
ulation of cell proliferation by ERα.
Methods
Chemicals and antibodies
Antibodies for ERα (F10), Ki-67 (H-300), cyclin A (C-19),
Cyclin B (H-20), cyclin D1 (H-295), cyclin E (C-19) wereBMC Cancer 2009, 9:31 http://www.biomedcentral.com/1471-2407/9/31
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obtained from Santa Cruz (Santa Cruz, CA). Blocking
peptides for ERα (F10), cyclin A (C-19), cyclin E (C-19)
were obtained from Santa Cruz (Santa Cruz, CA). Anti-
bodies for ERK1/2 (137F5), phospho-ERK1/2 (E10), AKT,
phospho-AKT/Ser473, and EGFR were obtained from Cell
Signaling Technology (Danvers, MA). Secondary antibody
conjugated with Alexa Fluor 488 (Molecular Probes, Inc,
Eugene, OR) was used for green fluorescent staining, sec-
ondary antibody conjugated with Rhodamine Red-X
(Jackson ImmunoResearch, West Grove, PA) was used for
red fluorescent staining. Heat inactivated FBS and Char-
coal-Dextrin stripped FBS (CD-FBS) were obtained from
Omega (Tarzana, CA). Estrogen was obtained from Sigma
(St. Louis, MO). ICI182780 was obtained from TOCRIS
(Ellisville, MO). Gefitinib was obtained from LC Labora-
tories (Woburn, MA). EGF was obtained from Invitrogen
(Carlsbad, CA).
Cell culture and treatments
DMEM/F12 medium (MediaTech Inc, Herndon, VA) con-
taining 10% heat inactivated FBS and 5 μg/ml insulin was
used for routine maintenance of the three ERα-positive
breast cancer cell lines, MCF-7, T47D, and ZR75-1
(ATCC). For experimental assays, phenol-red free DMEM/
F12 (MediaTech Inc, Herndon, VA) containing 5% CD-
FBS was used unless otherwise specified. To arrest cells in
G1 phase by ICI182780, cells were seeded in culture
dishes for 1–2 days to let the cells reach about 30–40%
confluency before replacement with medium containing
ICI182780. To evaluate the effect of estrogen stimulation,
cells were stimulated by adding E2 either after removal of
ICI182780 or in the presence of ICI182780. For estrogen
stimulation after removal of ICI182780, cells treated with
ICI182780 were washed briefly two times with serum-free
phenol red-free DMEM/F12 to remove ICI182780, fol-
lowed by replacement with medium containing 5 nM
estrogen but without ICI182780. The control cells were
replaced with medium containing vehicle only. For estro-
gen stimulation in the presence of ICI182780, cells were
treated with 10 nM ICI182780 for various times before
adding ten fold of E2 (100 nM) to the cells without
removing ICI182780. ICI182780 stock solution was
made at 10 mM in DMSO, then serially diluted in DMSO
to 10 μM before diluted in culture medium. Estrogen
stock solution was made at 10 mM in ethanol, then seri-
ally diluted in ethanol to 10 μM before diluted in culture
medium. To inhibit the EGFR activation, cells were treated
with Gefitinib for 2 hr first; without removing Gefitinib,
estrogen or EGF was then added to the cells for stimula-
tion. Gefitinib stock was made in DMSO at 1–50 mM, the
stock was diluted in culture medium to make the final
concentrations at 1–50 μM.
Immunofluorescent staining
Cells grown on glass coverslips were briefly washed with
ice-cold Dulbecco's PBS and fixed with cold 4% parafor-
maldehyde containing 0.01% Triton X-100 for 25 min on
ice. After washing once briefly with PBS-T (Dulbelcco's
PBS containing 0.01% Triton X-100), the cells were
treated with 0.05% Triton x-100 in PBS for 10 min for per-
meabilization. The cells were washed once briefly with
PBS-T, followed by blocking in PBS-T containing 5% nor-
mal serum and 50 mM NH4Cl for 30 min at room tem-
perature. The cells were then incubated with primary
antibodies diluted in PBS-T containing 1% normal serum.
Anti-ERα antibody was diluted at 1:50, anti-Ki-67 at
1:100, anti-cyclin D at 1:150, anti-cyclin E at 1:100, anti-
cyclin A at 1:100, and anti-cyclin B at 1:100. For the anti-
bodies with blocking peptides available, the antibodies
(ERα, cyclin A, cyclin E) were evaluated for its binding
specificity by incubation with 5 fold of blocking peptides
before applying to cells for primary antibody incubation.
After overnight incubation at 4°C, the cells were washed
four times with PBS-T, 7 min each time. Then the cells
were incubated for 1 hr at room temperature with fluores-
cent dye-conjugated secondary antibodies (1:200) in PBS-
T containing 1% normal serum. The cells were washed 4
times with PBS-T, 7 min each time before mounted on
slides with VectoShield with DAPI (Vector Laboratories,
Burlingame, CA). Immunofluorescent staining(s) was
observed under Olympus BX50 Fluorescence Microscope
with Optronics MagnaFire digital camera (Microscope
Image Center, UVM).
Flow cytometry analysis
For analysis of cell cycle distribution, cells were harvested
by trypsinization, pelleted by centrifugation, and washed
once with Dulbecco's PBS. While vortexing cells, ice-cold
70–75% ethanol was added drop wise to resuspend the
cells. The cells were fixed in 70% ethanol for at least 1 hr
at 4°C before staining or stored at -20°C freezer. Before
staining, 1–3 millions of cells were pelleted, washed once
with PBS, followed by resuspension in 1 ml PBS contain-
ing 20 μg/ml PI (propidium iodide), 150 μg/ml RNaseA,
10 mM EDTA, and 0.1% Triton X-100. Incubation was
carried in the dark at 37°C for 15–30 min. For the analysis
of cell cycle distribution of ERα-staining cells, cells were
harvested by trypsinization and the cell number counted.
The cells were pelleted by centrifugation (2000 rpm, 5
min, 4°C). After resuspension with culture medium, 3
million of cells were transferred into Ependorff tube and
pelleted by centrifugation (500 × g, 4°C, 2 min). The cell
pellet was resuspended in 1 ml PBS-T containing 1% para-
formaldehyde and cells were fixed on ice for 10 min. The
cells were pelleted by brief centrifugation, resuspended in
PBS containing 0.05% Triton-X100 for permeabilization
at room temperature for 5 min. After brief washing, cells
were incubated with 5% normal serum in PBS-T (30 min,
room temperature) for blocking. Cells were pelleted and
resuspended in PBS-T containing anti-ERα (F10, 1:100
dilution) and 0.5% BSA, followed by incubation at 4°C
for overnight. The cells were washed 4 times with PBS-T, 7BMC Cancer 2009, 9:31 http://www.biomedcentral.com/1471-2407/9/31
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min each, by centrifugation and resuspension, followed
by incubation with the secondary antibody anti-mouse
Alexa Fluor 488 (1:300) at room temperature for 40 min.
After washing with PBS-T for 4 times, 7 min each, the cells
were incubated with 0.5 ml PI-RNaseA solution for 30
min at 37°C. Flow cytometry analysis was performed
using the Coulter Epics XL-MCL (VCC core facility, UVM).
About 20,000 cells were analyzed for each sample.
Protein analysis by immuno-blotting
Cells at 70–80% confluence were washed briefly twice
with ice-cold D-PBS before scraping on ice with lysis
buffer (20 mM Tris-HCl, pH 7.5; 150 mM NaCl; 2.5 mM
sodium pyrophosphate; 1 mM sodium β-glycerophos-
phate; 5 mM NaF, 1 mM Na3VO4, 1 mM phenylmethyl-
sulfonyl fluoride, 1% Triton X-100, and 1 tablet of
protease inhibitor mixture (Roche Molecular Biochemi-
cals, Indianapolis, IN) per 40 ml of lysis buffer). Cellular
debris was removed by centrifugation (14,000 × g for 15
min at 4°C). For SDS-PAGE, total cell lysate containing
~30 μg proteins were separated on 12% SDS-PAGE gel
and transferred onto PVDF membranes (Millipore, Bed-
ford, MA). Immunoblotting was carried out followed
standard procedures [37,38].
Results
Colocalization of ER  and Ki67 in ER -positive breast 
cancer cell lines
ERα is not colocalized with the cell proliferation marker
Ki-67 in normal mammary cells, and colocalization of
ERα and Ki-67 is rare even in primary breast tumors [1-
3,16-18,23]. To study the mechanism of how cell prolifer-
ation is mediated by ERα, the ERα-positive breast cancer
cell lines were used in our study. In all the three ERα-pos-
itive cell lines evaluated in this study, i.e., MCF-7, T47D,
and ZR75-1, a large proportion of cells showed duel-stain-
ing of ERα and Ki-67 (Fig. 1). The colocalization of ERα
with Ki-67 was evaluated in cells under different culture
conditions and the duel-staining was observed in all cul-
ture conditions, including cell culture in regular DMEM/
F12 supplemented with 10% FBS, phenol-red free
DMEM/F12 supplemented with charcoal dextrin stripped
FBS, with and without insulin, with and without estrogen.
While these data don't exclude the possibility of a para-
crine regulation of cell proliferation by ERα in these cells,
the colocalization of ERα and Ki-67 does support the
hypothesis that ERα may mediate cell proliferation in an
autocrine mode in these ERα-positive breast cancer cell
lines, a mechanism absent in normal mammary cells and
most primary breast tumors [1-3,16-18,23,24].
Deregulated expression of ER  in all phases of cell cycle
In normal breast tissue, ERα is expressed in quiescent (G0)
cells or early G1 phase [1,17]. In MCF-7 cells, activation of
ERα leads to cyclin D1 and myc expression, indicating the
expression of ERα in G1 phase [26]. Ki-67 is a prolifera-
tion marker expressed in late G1, S, G2, and M phases of
the cell cycle [39]. In these ERα-positive breast cancer cell
lines, most Ki-67-staining cells contained high levels of
ERα suggesting that ERα might be present throughout the
cell cycle progression in these cell lines (Fig. 1). To address
this possibility, we evaluated the colocalization of ERα
with the cyclins for different phases of cell cycle (cyclin D
for G1 phase; cyclin E for late G1 phase; cyclin A for G1/
S/G2 phases; cyclin B for M phase) [40-42]. The cyclins for
the different phases of cell cycle were found colocalized
with a proportion of ERα cells, with the cyclin A showing
the largest and cyclin B the least proportion of ERα-stain-
Colocalization of ERα and Ki-67 in ERα-positive breast cancer cell lines Figure 1
Colocalization of ERα and Ki-67 in ERα-positive breast cancer cell lines. MCF-7, T47D, and ZR75-1 cells were co-
immunofluorescent stained for ERα (green) and Ki-67 (red). ERα-staining and Ki-67 staining were overlayed to show colocali-
zation (Merge). Nuclei were stained with DAPI. Shown here are photographs of cells grown in phenol-red free DMEM/F12 
containing 5% CD-FBS (200× magnification).BMC Cancer 2009, 9:31 http://www.biomedcentral.com/1471-2407/9/31
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ing cells (Fig. 2A). Furthermore, flow cytometry analysis
demonstrated that MCF-7 cells with high ERα expression
(ERαhigh) were distributed across G0/G1, S, and G2/M
phases (Fig. 2B). These data indicate that ERα expression
during cell cycle progression is deranged in MCF-7 cells.
E2 stimulation of ICI182780 treated cells induces 
expression of ER  and Ki-67
While the distribution of ERα across all phases of cell
cycling supports the autocrine mode of action in cell pro-
liferation, it also raises the possibility that the colocaliza-
tion of ERα with Ki-67 might be a coincidence. To further
determine whether ERα can mediate cell proliferation in
an autocrine mode, we sought to arrest the cells with the
pure ERα antagonist ICI182780 followed by estrogen
stimulation. When treated with ICI182780 for 72–96 hrs,
no cell was observed with high ERα expression and only a
few cells were stained with Ki-67, indicating that both ERα
and Ki-67 were down-regulated by ICI182780 (Fig. 3).
Consistently, ICI182780 treatment leads to cell cycle
arrest at G1 phase (Fig. 3). The inhibitory effect of
ICI182780 was observed similarly at concentrations from
10 nM to 50 nM, therefore 10 nM was selected for our
later experiments.
To evaluate the effect of estrogen stimulation, cells were
stimulated by adding E2 either after removal of
ICI182780 or in the presence of ICI182780. We first eval-
uated the effect of estrogen stimulation after removal of
ICI182780. MCF-7 cells were treated for ICI182780 for
72–96 hr and the treatment was stopped by washing with
fresh serum-free medium to remove ICI182780. The cells
were then stimulated with estrogen by adding medium
containing 5 nM estrogen but without ICI182780. The
control group of cells was replaced with medium without
estrogen. In the cells stimulated with estrogen, both ERα
and Ki-67 were induced with ERα and Ki-67 colocalized
in most cells (Fig. 4A). In the control group of cells with-
out estrogen stimulation, no high level of ERα or Ki-67
was observed although the cells were released from
ICI182780 treatment. We also determined the effect of
estrogen stimulation by adding estrogen directly to the
cells still under ICI182780 treatment (Fig. 4B). The con-
tinuous presence of ICI182780 was to help minimize the
secondary factors that might promote cell proliferation.
Cells were treated with 10 nM ICI182780 for 72–96 hrs
before the estrogen was added to the cells for a final con-
centration of 100 nM. Similar to the result shown in Fig.
4A, excessive estrogen stimulation in the presence of
ICI182780 also induced the expression of high levels of
ERα and Ki-67 with the two proteins colocalized in most
cells (Fig. 4B). Collectively, these data indicate that activa-
tion of ERα by estrogen in ICI182780 arrested cells
induces the expression of high levels of ERα and Ki-67
and their colocalization, supporting the autocrine mode
of ERα action.
E2 stimulation releases cell cycle arrest by ICI182780 to 
promote cell cycle progression
We next examined the effect of estrogen stimulation on
cell cycle progression. As described above, cells were stim-
ulated with estrogen either after release from ICI182780,
or estrogen was added at 10 fold higher concentration
(100 nM E2) directly to cells without removing
ICI182780 (10 nM ICI). Similar results were observed for
either stimulation (Fig. 5, and data not shown). In cells
stimulated with estrogen after release from ICI182780,
most cells were still in the G1 phase until 24 hr after stim-
ulation. At 44 hr after estrogen stimulation, about 45% of
the cells were in S or G2/M phases, indicating that activa-
tion of ERα promotes the progressing of the cell cycle (Fig.
5). Interestingly, induction of high levels of ERα and Ki-
67 appeared much earlier, with high levels of ERα
appeared at around 6 hr. It is noteworthy that high levels
of ERα appeared earlier than Ki-67, supporting that the
activation of ERα is mediating the expression of Ki-67 and
the cell cycle progression. These data indicate that the
colocalization of ERα and Ki-67 is not a coincidence and
support the hypothesis that activation of ERα can pro-
mote cell proliferation by autocrine regulation.
EGFR signaling is not required for the autocrine regulation 
of cell proliferation by ER
In the paracrine regulation of cell proliferation by ERα,
EGFR signaling is required [20]. Therefore we evaluated
whether EGFR signaling is required for the autocrine reg-
ulation of cell proliferation by ERα in MCF-7 cells. EGFR
inhibitor Gefitinib was used to block EGFR signaling, 20
μM of Gefitinib was chosen based on our preliminary
experiments using a wide range concentrations of Gefit-
inib (1 μM – 50 μM) (Fig. 6D, and data not shown). We
first evaluated whether Gefitinib treatment inhibits E2
stimulation induced expression and colocalization of ERα
and Ki-67. MCF-7 cells were treated first with 10 nM
ICI182780 for 72–96 hr, followed by adding the EGFR
inhibitor Gefitinib to a final concentration of 20 μM for 2
hr, then by adding estrogen to a final concentration of 100
nM. In the presence of ICI182780 and Gefitinib, estrogen
stimulation still induced the expression and colocaliza-
tion of ERα and Ki-67 (Fig. 6B). Conceivably, Gefitinib
treatment does not inhibit estrogen stimulation induced
cell cycle progression (Fig. 6C lower panel). In the control
groups of MCF-7 cells treated with ICI182780 for 72–96
hr, ERα and Ki-67 were down-regulated and the cells
remained at G1 phase (Fig. 6A, C upper panel). In the
growth curve studies and the EGF stimulation experi-
ments, Gefitinib at 20 μM is sufficient to block EGFR sig-
naling but not toxic to the cells (Fig. 6D, and data not
shown). From these data, we concluded that EGFR signal-BMC Cancer 2009, 9:31 http://www.biomedcentral.com/1471-2407/9/31
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Deregulated expression of ERα in the cell cycle in MCF-7 cells Figure 2
Deregulated expression of ERα in the cell cycle in MCF-7 cells. A, co-immunofluorescent staining for ERα (green fluo-
rescence) and the major cyclins (D, E, A, and B) (red fluorescence). Cells were immunofluorescent stained with antibody for 
ERα and the antibody for one of the cyclins, followed by secondary antibody. Colocalization was shown by overlaying (Merge). 
Magnification, 200×. B, Flow cytometry analysis for the cell cycle distribution of ERαhigh cells (cells with high levels of ERα). 
Cells were stained with antibody for ERα followed by Alexa Fluor 488, and nuclear DNA was stained with propidium iodide 
(PI).BMC Cancer 2009, 9:31 http://www.biomedcentral.com/1471-2407/9/31
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ICI182780 treatment of MCF-7 cells leads to ERα down-regulation and cell cycle arrest Figure 3
ICI182780 treatment of MCF-7 cells leads to ERα down-regulation and cell cycle arrest. A, Down-regulation of 
ERα by 10 nM ICI182780 treatment for 60–96 hrs. ERα and Ki-67 were evaluated by immunofluorescent staining, nuclei were 
stained with DAPI. Cells without ICI182780 treatment were used as control. Magnification, 200×. B, flow cytometry analysis of 
cell cycle distribution. Shown here is the cell cycle distribution of non-treated control cells, and cells treated with 10 nM 
ICI182780 for 48–72 hr. ICI182780 treatment was carried out in phenol-red free DMEM/F12 containing 5% CD-FBS.BMC Cancer 2009, 9:31 http://www.biomedcentral.com/1471-2407/9/31
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ing is not required for the autocrine action of ERα in
mediating cell proliferation in MCF-7 cells.
Discussion
ERα is the primary estrogen receptor mediating the effects
of estrogen in normal mammary epithelial cells [1-3,5-
9,43]. In breast cancer, abnormal expression of ERα is
found in about 70% of primary tumors [10,13]. Despite
the significant role of ERα, the mechanism of how ERα
mediates cell proliferation is not fully understood. The
dissociation of ERα with cell proliferation markers such as
Ki-67 in the normal mammary gland leads to the para-
crine model of ERα-mediated cell proliferation. While
colocalization of ERα and Ki-67 is rare in most primary
breast cancers, there do exist some cancer cells in some
primary breast tumors showing colocalization of ERα and
Ki-67 suggesting the possibility of autocrine regulation. In
this paper using the ERα-positive breast cancer lines, we
presented data showing that most Ki-67 staining cells
expressed high levels of ERα and that cells with high levels
of ERα are distributed across different phases of cell cycle.
We further demonstrated that activation of ERα in
ICI182780 arrested cells can induce the expression and
colocalization of high levels of ERα and Ki-67, and more
importantly, the progressing of cell cycles from G1 phase
to the G2/M phases. Collectively, our data support the
hypothesis that ERα can mediate cell proliferation in an
autocrine mode in these ERα-positive breast cancer cell
lines.
Whether ERα mediates cell proliferation by autocrine
and/or paracrine regulation is related to whether ERα-pos-
itive cells can proliferate or not. Inferred from the para-
crine model is that ERα-positive cells are a separate sub-
population of cells that don't proliferate, or even further
that ERα-positive cells cannot proliferate because ERα
inhibits the proliferation of ERα-positive cells [1,3,44,45].
Although ERα is known to promote cell proliferation in
ERα-positive breast cancer cell lines such as MCF-7, exog-
enous overexpression of ERα in some cell lines such as
MDA-MB-231 and MCF-10A does inhibit cell prolifera-
tion [46-50]. The mechanism of how ERα mediates cell
proliferation may have clinical implication for breast can-
cer etiology and therapy. Malignant transformation is a
multistep process that involves different combination of
genes at different stage of malignancy [51]. Distinct sets of
ERα-target genes might be involved for the autocrine ver-
sus paracrine regulation and it will be interesting to exam-
ine whether the resistance to endocrine-related therapy is
correlated with the mode of ERα action.
All the three ERα-positive cell lines used in our study
showed colocalization of ERα and Ki-67. Since the
number of established ERα-positive breast cancer cell
lines is much less than expected from the expression fre-
quency of ERα in primary breast tumors, we speculated
that ERα-positive cell lines could only be established from
cancer cells with autocrine regulation in the primary
tumors [13,52]. In that case, what is known about the
E2 stimulation of ICI182780 treated cells induced the expression and colocalization of ERα and Ki-67 Figure 4
E2 stimulation of ICI182780 treated cells induced the expression and colocalization of ERα and Ki-67. A, E2 
stimulation of cells released from ICI182780 treatment. MCF-7 cells were treated with ICI182780 for 72–96 hr, then 
ICI182780 was removed by washing with serum-free medium. After removal of ICI182780, cells were treated by 5 nM E2 for 
24 hr; control cells were replaced with medium without E2. Magnification, 200×. B, stimulation of E2 by adding E2 directly to 
cells under ICI182780 treatment. Cells were treated with 10 nM ICI182780 for 72–96 hr, then 100 nM E2 was added directly 
to the cells without removing ICI182780 for estrogen stimulation. The expression of ERα and Ki-67 was evaluated by immun-
ofluorescent staining. Overlay of the ERα-staining and Ki-67 staining showed the colocalization (Merge). DAPI was used for 
nuclear staining. Magnification, 200×.BMC Cancer 2009, 9:31 http://www.biomedcentral.com/1471-2407/9/31
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breast cancer from the studies using the ERα-positive
breast cancer cell lines may not apply to all the ERα-posi-
tive primary breast tumors. It needs to point out that
although our data support the autocrine mode of ERα
action, it remains to determine whether both autocrine
and paracrine modes of action by ERα are involved in
these ERα-positive breast cancer cell lines. ERα is
expressed in both the nucleus and cell surface in MCF-7
cells [53,54]. Based on the levels of membrane ERα, MCF-
7 cells can be separated into two sub-populations, mERα-
high and mERαlow [55,56]. The levels of nuclear ERα also
showed heterogeneity in MCF-7 cells. It is not clear
whether the heterogeneity of nuclear ERα levels is caused
by the differential expression of ERα during cell cycle pro-
gression or by the heterogeneous sub-populations of cells.
As demonstrated in ICI182780 treated cells, even
extremely low or basal level of ERα can mediate some of
the cellular response to estrogen. To determine whether
paracrine regulation is involved or not, a subline of MCF-
7 with the ERα being completely shut off, i.e., eliminating
the low basal level of ERα, will be needed to test their pro-
liferation in response to estrogen when mixed with nor-
mal MCF-7 cells.
Together with the systemic hormones, growth factors are
involved in mammary cell proliferation. EGFR signaling is
essential for ERα-mediated cell proliferation in the nor-
mal mammary glands [20]. In MCF-7 cells, EGFR is
involved in the non-genomic action of ERα and blocking
of some EGFR activated pathways could inhibit ERα-
mediated cell proliferation [33-36]. Our data, however,
indicate that EGFR signaling is not required for the auto-
crine regulation of cell proliferation by ERα.
Conclusion
ERα can mediate estrogen-induced cell proliferation in an
autocrine mode in ERα-positive breast cancer cell lines.
All of the three ERα-positive cell lines used in our study
Time course of E2 induced expression of ERα and Ki-67 and cell cycle progression Figure 5
Time course of E2 induced expression of ERα and Ki-67 and cell cycle progression. MCF-7 cells were treated with 
ICI182780 for 72–96 hr and ICI182780 treatment was stopped by washing with serum-free medium. After removal of 
ICI182780, cells were treated with 5 nM E2 for various lengths of time (from 2 hr to 44 hr). Cells grown on coverslips were 
immunofluorescent stained for ERα and Ki-67. Nuclei were stained with DAPI. Cells grown on regular culture dishes were col-
lected for PI staining and analyzed by flow cytometry for cell cycle progression. Magnification, 200×.BMC Cancer 2009, 9:31 http://www.biomedcentral.com/1471-2407/9/31
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EGFR signaling is not required for the autocrine regulation of cell proliferation by ERα Figure 6
EGFR signaling is not required for the autocrine regulation of cell proliferation by ERα. A, MCF-7 cells treated 
with 10 nM ICI182780 for 72–96 hr, showing the down-regulation of ERα and Ki-67 by ICI182780 treatment. In A and B, ERα 
and Ki-67 were evaluated by immunofluorescent staining, nuclei were stained with DAPI. ERα-staining and Ki-67 staining were 
overlayed to show colocalization (Merge). Magnification, 400×. B, EGFR inhibitor Gefitinib does not inhibit E2 induced ERα and 
Ki-67 expression. MCF-7 cells were stimulated with 100 nM E2 in the presence of 10 nM ICI182780 and 20 μM EGFR inhibitor 
Gefitinib. MCF-7 cells were treated first with 10 nM ICI182780 for 72–96 hr, followed by adding the EGFR inhibitor Gefitinib 
to a final concentration of 20 μM for 2 hr, before adding estrogen to a final concentration of 100 nM for 16 hr. C, flow cytom-
etry analysis of cell cycle progression, showing E2 stimulated cell cycle progression is not inhibited by Gefitinib. Upper panel, 
MCF-7 cells treated with ICI182780 for 72 hr. The cells were arrested at G1 phase. Lower panel, cell cycle progression was 
stimulated by 100 nM E2 in the presence of 10 nM ICI182780 and 20 μM EGFR inhibitor Gefitinib. MCF-7 cells were treated 
first with 10 nM ICI182780 for 72 hr, followed by treatment with the Gefitinib (20 μM) for 2 hr, before stimulation with 100 
nM E2 for 36 hr. D, immunoblotting of phosphorylated ERK1/2, showing the inhibition of EGFR signaling by 20 μM Gefitinib. 
MCF-7 cells were serum starved for 24 hr, followed by treatment with 20 μM Gefitinib for 2 hr, before EGF stimulation for 5 
min. The control group of cells was not treated with Gefitinib. Phosphorylation of ERK1/2 was used to assess the activation of 
the EGFR signaling.BMC Cancer 2009, 9:31 http://www.biomedcentral.com/1471-2407/9/31
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showed colocalization of ERα and Ki-67, indicating that
these cell lines might be originated from primary tumor
cells with autocrine regulation. Considering that the
number of established ERα-positive breast cancer cell
lines is much less than expected from the percentage of
ERα-positive primary breast tumors, we speculated that
ERα-positive cell lines could only be established from
cancer cells with autocrine regulation in the primary
tumors. In that case, what is learnt about the breast cancer
from the studies using the ERα-positive breast cancer cell
lines may not apply to all the ERα-positive primary breast
tumors.
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